EXECUTION COPY

 
NON-COMPETITION AGREEMENT
 
This NON-COMPETITION AGREEMENT (this “Agreement”) is dated as of December 23,
2010, by and among Dr. Ryuji Ueno, as trustee of the Ryuji Ueno Revocable Trust
under Trust Agreement dated December 20, 2002 (the “Ueno Trust”), and Dr.
Sachiko Kuno as trustee of the Sachiko Kuno Revocable Trust under Trust
Agreement dated December 20, 2002 (the “Kuno Trust”) (each a “Shareholder” and
collectively, the “Shareholders”), Dr. Ryuji Ueno, an individual (“Ueno”), and
Dr. Sachiko Kuno, an individual (“Kuno” and collectively with Ueno, the
“Principals” and together with the Shareholders, each a “Seller” and
collectively, the “Sellers”), and Ambrent Investments S.à r.l., a company
organized under the laws of Luxembourg (the “Purchaser”), and Sucampo
Pharmaceuticals, Inc., a Delaware corporation (the “Parent”).  Any capitalized
terms used but not defined in this Agreement have the respective meanings set
forth in the SPA (as defined below).
 
RECITALS
 
WHEREAS, the Shareholders are the owners of 100% of the issued and outstanding
shares of capital stock of Sucampo AG (the “Shares”), a company organized under
the laws of Switzerland (the “Company”);
 
WHEREAS, the Company is the owner of 100% of the issued and outstanding shares
of capital stock of Sucampo AG Japan Ltd., a company organized under the laws of
Japan (the “Subsidiary”).
 
WHEREAS, the Parent is the owner of 100% of the issued and outstanding shares of
capital stock of the Purchaser.
 
WHEREAS,  the Sellers, on the one hand, and the Purchaser and the Parent, on the
other hand, have entered into a Stock Purchase Agreement, dated as of the date
hereof (the “SPA”), pursuant to which the Shares will be purchased by the
Purchaser; and
 
WHEREAS, in order to induce the Purchaser and the Parent to enter into the SPA
and to minimize the risk that the Purchaser and/or the Parent will lose the
benefit of the goodwill and the Shares being purchased by it and/or them, and to
protect the trade secrets and other confidential and proprietary information
known to the Sellers and being acquired by the Purchaser and the Parent, the
Sellers have agreed to restrict their activities in accordance with the terms
and conditions of this Agreement.
 
NOW, THEREFORE, in consideration of the promises, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereby agree as follows:
 
 

--------------------------------------------------------------------------------

 
 
AGREEMENT

1.           Covenant Not To Compete.
 
(a)           For the period beginning on the Closing and ending five (5) years
thereafter (the “Non-Compete Period”), the Sellers shall not, directly or
indirectly, including without limitation as an officer, director, proprietor,
employee, independent contractor, partner, member, investor, guarantor,
consultant, advisor, agent, sales representative or other participant, engage in
or assist with any Competitive Activity (as defined in Section 1(b), below) in
any country in the World in which the Sellers, the Company, and/or the
Subsidiary, during the immediately prior 3-year period, has been or at the time
of the Closing is, engaged.  The Sellers understand the foregoing restrictions
may limit their respective abilities to engage in certain business during the
Non-Compete Period; however, they also acknowledge and agree that they will
receive sufficiently high remuneration and other benefits under the SPA to
justify these restrictions.
 
(b)           For purposes of this Agreement, “Competitive Activity” shall mean:
(i) the research, development and/or commercialization of medicines based on
Prostones or drug therapy that have been, are, could be or will be developed
from any idea, invention or innovation relating to Prostones or from any
intellectual property owned by or held by the Company or the Subsidiary; and
(ii) the creation or development of, application for, ownership or holding of,
protection of, and/or licensing of patents and/or patent applications relating
to Prostone technology and/or patents or relating to other similar drug therapy
that have been, are, could be or will be developed from any intellectual
property owned by or held by the Company or the Subsidiary.  The definition of
Competitive Activity shall not include any currently ongoing unpaid scientific
and/or clinical advice provided by the Principals on behalf of R-Tech Ueno in
connection with the development or marketing of Rescula.  Should the Principals
seek an exception to the definition of Competitive Activity for any currently
ongoing paid or unpaid scientific and/or clinical advice provided by the
Principals on behalf of R-Tech Ueno or for other services related to Rescula
provided by the Principals on behalf of R-Tech Ueno, whether paid or unpaid
(such as membership on a Board of Directors or speaking engagements at medical
conferences), the Principals must follow the policies and procedures for review,
approval or ratification of such activities as set forth in Section 2 of the
Sucampo Pharmaceuticals, Inc. Related Person Transactions Policy, which is
attached hereto as Exhibit A, prior to engaging in such activities and/or
receiving such compensation.  The Company shall issue a determination regarding
whether any request for an exception is granted.  The Company’s decision on any
such request shall be made in the Company’s sole discretion, but approval of the
request shall not be unreasonably withheld.
 
(c)           Nothing in Section 1(a) shall be construed so as to preclude
Sellers from (i) investing in any publicly or privately held company provided
that such Seller’s beneficial ownership or rights to ownership of any class of
such company’s securities does not exceed 5% of the outstanding securities of
such class or (ii) owning, managing or participating in R-Tech Ueno; provided,
however, that the Sellers may not engage in Competitive Activity as a result of
their ownership, management or participation in said entity.
 
2.           Non-Solicitation.
 
(a)           Employees/Contractors/Consultants. During the Non-Compete Period,
the Sellers shall not directly or indirectly induce, solicit, recruit, or
encourage or attempt to induce, solicit, recruit, or encourage (regardless of
who initiates the contact) any person then employed or retained by the
Purchaser, the Parent or an affiliate or any person employed or retained by the
Purchaser, the Parent or an affiliate within the prior year, whether as an
officer, employee, independent contractor, consultant or advisor, to leave such
employment or retention of the Purchaser, the Parent or an affiliate, to cease
providing or to otherwise alter the services then provided to the Purchaser, the
Parent or to an affiliate.
 
 
2

--------------------------------------------------------------------------------

 

(b)           Customers/Suppliers, Distributors/Licensees.  During the
Non-Compete Period, the Sellers shall not, directly or indirectly, induce,
solicit, encourage, or attempt to induce, solicit or encourage (regardless of
who initiates the contact) any customer, supplier, distributor, licensee or any
other person or entity who maintains a business relationship with the Purchaser,
the Parent, the Sellers, the Company, or the Subsidiary to stop or alter the
manner in which they are then doing business with the Purchaser, the Parent, the
Sellers, the Company, or the Subsidiary.
 
3.           Separate Covenants.  The terms and provisions of the covenants
contained in Sections 1 and 2 above are intended to be separate and divisible
provisions and if, for any reason, any one or more of the sections or
subsections are held to be invalid or unenforceable, the validity or the
enforceability of any other provision of this Agreement shall not thereby be
affected.  If, in any judicial proceeding, a court shall refuse to enforce any
of the separate covenants (or any part thereof) contained in Sections 1 or 2
then such unenforceable covenants (or any such part) shall be deemed eliminated
from this Agreement for the purpose of those proceedings to the extent necessary
to permit the remaining separate covenants (or portions thereof) to be enforced.
 
(a)           Reformation.  Each party hereto acknowledges that the potential
restrictions on the Sellers’ future activities imposed by the covenants in
Sections 1 and 2 are reasonable in both duration and scope and in all other
respects.  In the event that the provisions of Sections 1 or 2 should ever be
deemed to exceed the duration or scope permitted by applicable law, then such
provisions shall be reformed to the maximum time, scope or other limitation, as
the case may be, permitted by applicable law, and each party agrees that the
restrictions and prohibitions contained herein shall be effective to the fullest
extent allowed under applicable law in such jurisdiction.
 
(b)           Specific Performance.  The Sellers acknowledge that it would be
impossible to determine the amount of damages that would result from any breach
of any of the provisions of Sections 1 or 2 and that the remedy at law for any
breach, or threatened breach, of any of such provisions would likely be
inadequate and, accordingly, agrees that the Purchaser and/or the Parent shall,
in addition to any other rights or remedies which it and/or they may have at law
or in equity, be entitled to seek such equitable and injunctive relief as may be
available from any court of competent jurisdiction to restrain the Sellers from
violating any of such provisions of this Agreement.  In connection with any
action or proceeding for such equitable or injunctive relief, the Sellers hereby
waive any claim or defense that a remedy at law alone is adequate and agree, to
the maximum extent permitted by law, to have each such provision of Sections 1
and 2 specifically enforced against them, without the necessity of posting bond
or other security, and consent to the entry of equitable or injunctive relief
against them enjoining or restraining any breach or threatened breach of any of
the provisions of Sections 1 or 2.
 
(c)           Survival.  Any breach of this Agreement by either or all of the
Sellers, the Purchaser or the Parent shall have no effect on the continuing
operation of Sections 1 or 2.
 
 
3

--------------------------------------------------------------------------------

 

4.           Miscellaneous.
 
(a)           Amendment; Waiver.  This Agreement shall not be amended, altered
or modified in any manner whatsoever, except by a written instrument executed by
the parties hereto.  No waiver of any breach or default hereunder shall be
considered valid unless in writing and signed by the party giving such waiver,
and no such waiver shall be deemed a waiver of any subsequent breach of the same
or similar nature.
 
(b)           Governing Law.  The interpretation and construction of this
Agreement, and all matters relating hereto, will be governed by the laws of the
State of Maryland applicable to contracts made and to be performed entirely
within the State of Maryland without giving effect to any conflict of law
provisions thereof.
 
(c)           Jurisdiction.  Any legal action or proceeding with respect to this
Agreement may be brought in the courts of the State of Maryland in Montgomery
County or of the United States District Court for the District of Maryland and,
by execution and delivery of this Agreement, each of the Sellers, the Purchaser
and the Parent hereby accept for themselves and in respect of their property,
generally and unconditionally, the jurisdiction of the aforesaid courts.  Each
of the Sellers, the Purchaser and the Parent irrevocably consent to the service
of process out of any of the aforementioned courts in any such action or
proceeding by the delivery of notice as provided in Section 4(d) below, such
service to become effective thirty (30) days after such delivery.
 
(d)           Notices.  Any notice or other communication required or permitted
under this Agreement shall be in writing and shall be deemed to have been given
(i) if personally delivered, when so delivered, (ii) if mailed, one week after
having been placed in the United States mail, registered or certified, postage
prepaid, addressed to the party to whom it is directed at the address listed
below or (iii) if given by facsimile, when the notice is transmitted to the
facsimile number specified below, and the appropriate answerback or telephonic
confirmation is received:
 
 
If to the Shareholders:
Ryuji Ueno Revocable Trust/Sachiko Kuno Revocable Trust

 24687 Yacht Club Road
St. Michaels, MD 20854

 
with a copy to:
Dorsey & Whitney LLP

Suite 1500, 50 South Sixth Street
Minneapolis, MN 55402-1498
Attention: William Berens, Esq.
Tel: 612.340.2621
Fax: 612.340.8827

 
If to the Principals:
Dr. Ryuji Ueno/Dr. Sachiko Kuno

7501 Wisconsin Avenue, Suite 600
Bethesda, MD 20814
Tel: (301) 941-8111
Fax: (301) 961-3076

 
4

--------------------------------------------------------------------------------

 

 
with a copy to: 
McGuireWoods LLP
2001 K Street, N.W., Suite 400
Washington, DC 20006-1040
Attention: Douglas W. Charnas, Esq.
Tel: (202) 857-1757
Fax: (202) 828-2980 

 

 
If to Purchaser or Parent:
Sucampo Pharmaceuticals, Inc.
4520 East West Highway, Third Floor
Bethesda, MD 20814
Attention: Thomas J. Knapp, Esq., General Counsel
Tel: (240) 223-3627
Fax: (301) 961-3440

 

  with a copy to 
Manatt, Phelps & Phillips, LLP
11355 W. Olympic Boulevard
Los Angeles, CA  90064
Attention: Gordon M. Bava, Esq.
                   David M. Grinberg, Esq.
Tel:  (310) 312-4000
Fax: (310) 312-4224

 
(e)           Entire Agreement.  This Agreement and the Stock Purchase
Agreement, including the Exhibits, Schedules, the Disclosure Schedule and other
documents referred to therein, constitute the entire agreement of the parties
hereto with reference to the transactions contemplated hereby and supersede all
other prior agreements, understandings, representations and warranties, both
written and oral, between the parties or their respective representatives,
agents or attorneys, with respect to the subject matter hereof.
 
(f)           Parties In Interest.  This Agreement shall be binding upon and
inure solely to the benefit of each party hereto and their respective
successors, assigns, estate, heirs, executors, administrators and other legal
representatives, as the case may be.  Nothing in this Agreement, express or
implied, is intended to confer upon any other person or entity, other than
parties hereto and their respective successors, assigns, estate, heirs,
executors, administrators and other legal representatives, as the case may be,
any rights, remedies, obligations or liabilities under or by reason of this
Agreement.
 
(g)           Assignment.  This Agreement shall not be assignable by law or
otherwise without the prior written consent of the other parties hereto;
provided, however, that the Purchaser and/or the Parent may assign any of its
and/or their rights and obligations hereunder to any of its and/or their
affiliates or to any other entity which may acquire all or substantially all of
the assets, shares or business of the Purchaser, the Parent or any of its and/or
their affiliates or any entity with or into which the Purchaser, the Parent or
any of its and/or their affiliates may be consolidated or merged.
 
 
5

--------------------------------------------------------------------------------

 

(h)           Compliance.  The Purchaser’s and /or the Parent’s failure to
insist upon strict compliance with any provision of this Agreement or the
failure to assert any right that the Purchaser and/or the Parent may have
hereunder shall not be deemed to be waiver of such provision or right or any
other provision or right of this Agreement.
 
(i)            Advice of Counsel.  Each of the Sellers acknowledges that, in
executing this agreement, he, she or it has had the opportunity to seek the
advice of independent legal counsel, and has read and understood all of the
terms and provisions of this Agreement.  This Agreement shall not be construed
against any party by reason of the drafting or preparation hereof.
 
(j)            Headings.  The section headings herein are for convenience of
reference only, do not constitute part of this Agreement and shall not be deemed
to limit or otherwise affect any of the provisions hereof.
 
(k)           Severable Provisions.  The provisions of this Agreement are
separate and distinct, and if any provisions are determined to be unenforceable,
in whole or in part, the remaining provisions, and the enforceable parts of any
partially unenforceable provisions, shall nevertheless be enforceable.
 
(l)            Counterparts.  This Agreement may be executed in one or more
counterparts (including by facsimile), each of which shall be deemed to be an
original, but all of which shall constitute one and the same instrument.
 
[remainder of page intentionally left blank; signature page(s) follow]
 
 
6

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first written above.
 
“SELLERS”
 
“PURCHASER”
     
RYUJI UENO REVOCABLE TRUST UNDER
TRUST AGREEMENT DATED DECEMBER 20, 2002
 
AMBRENT INVESTMENTS S.À R.L., a
Luxembourg company
         
By: 
/s/ Ryuji Ueno  
By: 
/s/ James J. Egan  
Name: Ryuji Ueno
   
Name:  James J. Egan
 
Title: Trustee
   
Title:  Authorized Person
         
SACHIKO KUNO REVOCABLE TRUST UNDER
TRUST AGREEMENT DATED DECEMBER 20, 2002
 
“PARENT”
       
By:
 
/s/Sachiko Kuno
 
SUCAMPO PHARMACEUTICALS, INC.,
a Delaware corporation
 
Name: Sachiko Kuno
       
Title: Trustee
           
By:
/s/ James J. Egan
/s/ DR. RYUJI UENO
   
Name:  James J. Egan
DR. RYUJI UENO
   
Title:  Chief Operating Officer
       
/s/ DR. SACHIKO KUNO
     
DR. SACHIKO KUNO
     

 
7

--------------------------------------------------------------------------------